theory clinical_30_9
imports Main

begin

typedecl entity
typedecl event

consts
  Mutation :: "entity ⇒ bool"
  Activating :: "entity ⇒ bool"
  CTNNB1 :: "entity ⇒ bool"
  Cell :: "entity ⇒ bool"
  βCatenin :: "entity ⇒ bool"
  Proliferation :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  Via :: "event ⇒ entity ⇒ bool"
  Inhibit :: "event ⇒ bool"
  Cause :: "event ⇒ entity ⇒ bool"
  Reduce :: "event ⇒ bool"
  Stop :: "event ⇒ bool"
  Reduction :: "event ⇒ bool"
  Cessation :: "event ⇒ bool"
  Treat :: "event ⇒ bool"
  CrucialStep :: "event ⇒ event ⇒ bool"
  Address :: "event ⇒ entity ⇒ bool"
  Directly :: "event ⇒ bool"
  Make :: "event ⇒ bool"
  Effective :: "event ⇒ bool"
  Treatment :: "event ⇒ bool"
  Purpose :: "event ⇒ entity ⇒ bool"
  Pathway :: "entity ⇒ bool"
  Lead :: "event ⇒ entity ⇒ bool"
  Contribute :: "event ⇒ bool"
  Success :: "event ⇒ bool"
  Thereby :: "event ⇒ bool"
  Enhance :: "event ⇒ event ⇒ bool"
  Target :: "event ⇒ entity ⇒ bool"
  Responsible :: "event ⇒ entity ⇒ bool"
  By :: "event ⇒ bool"
  Ensure :: "event ⇒ bool"

(* Explanation 1: Activating mutations of CTNNB1 promote the proliferation of cells via β-catenin. *)
axiomatization where
  explanation_1: "∃x y z e. Mutation x ∧ Activating x ∧ CTNNB1 y ∧ Cell z ∧ βCatenin y ∧ Proliferation e ∧ Agent e x ∧ Patient e z ∧ Via e y"

(* Explanation 2: Inhibiting β-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB1, and this reduction or cessation is a crucial step in treating these mutations. *)
axiomatization where
  explanation_2_1: "∃x y z e1 e2. Inhibit e1 ∧ βCatenin x ∧ Cell y ∧ Mutation z ∧ Activating z ∧ CTNNB1 z ∧ Proliferation e2 ∧ Agent e1 x ∧ Patient e2 y ∧ Cause e2 z ⟶ (Reduce e1 ∨ Stop e1)"
axiomatization where
  explanation_2_2: "∃x y e1 e2. Reduction e1 ∧ Cessation e1 ∧ Mutation x ∧ Treat e2 ∧ Agent e2 y ∧ Patient e2 x ⟶ CrucialStep e1 e2"

(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting β-catenin directly addresses the underlying cause of cell proliferation, making it an effective treatment for patients with activating CTNNB1 mutations. *)
axiomatization where
  explanation_3_1: "∃x y z e1 e2. (Reduce e1 ∨ Stop e1) ∧ Proliferation e2 ∧ Cell x ∧ Cause e2 y ∧ Inhibit e1 ∧ βCatenin z ∧ Agent e1 z ∧ Patient e2 x ∧ Address e1 y ∧ Directly e1"
axiomatization where
  explanation_3_2: "∃x y z e1 e2. Make e1 ∧ Effective e2 ∧ Treatment e2 ∧ Patient e2 x ∧ Mutation y ∧ Activating y ∧ CTNNB1 z ∧ Agent e1 x ∧ Patient e1 x ∧ Purpose e1 y"

(* Explanation 4: The effectiveness of inhibiting β-catenin as a treatment is due to its ability to target the specific pathway that leads to cell proliferation in patients with activating CTNNB1 mutations, thereby directly contributing to the treatment's success. *)
axiomatization where
  explanation_4_1: "∃x y z w e1 e2 e3. Effective e1 ∧ Inhibit e2 ∧ βCatenin x ∧ Treatment e1 ∧ Pathway y ∧ Cell z ∧ Proliferation e3 ∧ Patient e3 w ∧ Mutation w ∧ Activating w ∧ CTNNB1 w ∧ Target e2 y ∧ Lead e3 z ∧ Agent e2 x ∧ Patient e3 z ∧ Cause e1 w"
axiomatization where
  explanation_4_2: "∃x y e1 e2. Contribute e1 ∧ Success e2 ∧ Treatment e2 ∧ Directly e1 ∧ Thereby e1 ∧ Agent e1 x ∧ Patient e1 y"

(* Explanation 5: Inhibiting β-catenin not only reduces cell proliferation but also enhances the effectiveness of treatment for patients with activating CTNNB1 mutations by directly targeting the pathway responsible for cell proliferation, ensuring the treatment is effective. *)
axiomatization where
  explanation_5_1: "∃x y z e1 e2 e3. Inhibit e1 ∧ βCatenin x ∧ Proliferation e2 ∧ Cell y ∧ Effective e3 ∧ Treatment e3 ∧ Patient e2 z ∧ Mutation z ∧ Activating z ∧ CTNNB1 z ∧ Reduce e1 ∧ Enhance e1 e3 ∧ Purpose e1 z"
axiomatization where
  explanation_5_2: "∃x y e1 e2. Target e1 x ∧ Pathway x ∧ Proliferation e2 ∧ Cell y ∧ Responsible e2 x ∧ Directly e1 ∧ By e1 ∧ Agent e1 x ∧ Patient e1 y"
axiomatization where
  explanation_5_3: "∃x e. Ensure e ∧ Treatment x ∧ Effective x ∧ Agent e x"

theorem hypothesis:
  assumes asm: "βCatenin x ∧ Patient e1 y ∧ Mutation y ∧ Activating y"
  (* Hypothesis: Inhibiting β-catenin may be effective in treating patients with activating CTTNB1 mutations *)
  shows "∃x y e1 e2. Inhibit e1 ∧ βCatenin x ∧ Patient e1 y ∧ Mutation y ∧ Activating y ∧ Agent e1 x ∧ Patient e1 y ∧ Treat e2 ∧ Agent e2 x ∧ Patient e2 y ⟶ Effective e2"
proof -
  (* From the known information, we have βCatenin x, Patient e1 y, Mutation y, and Activating y. *)
  from asm have "βCatenin x ∧ Patient e1 y ∧ Mutation y ∧ Activating y" <ATP>
  (* We need to show that inhibiting β-catenin may be effective in treating patients with activating CTNNB1 mutations. *)
  (* From the logical relation Implies(D, H), we know that inhibiting β-catenin implies the effectiveness of treatment. *)
  (* We also have Implies(D, F), which means inhibiting β-catenin implies treatment for activating CTNNB1 mutations. *)
  (* Therefore, if we can show that inhibiting β-catenin occurs, we can conclude the effectiveness of treatment. *)
  (* From the derived implication Implies(D, H), we can directly infer the effectiveness of treatment. *)
  have "Inhibit e1 ∧ βCatenin x ∧ Patient e1 y ∧ Mutation y ∧ Activating y ⟶ Effective e2" <ATP>
  then show ?thesis <ATP>
qed

end
